Sulfoxides in medicine.
Journal
Current opinion in chemical biology
ISSN: 1879-0402
Titre abrégé: Curr Opin Chem Biol
Pays: England
ID NLM: 9811312
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
30
03
2023
revised:
13
05
2023
accepted:
16
05
2023
medline:
22
9
2023
pubmed:
12
6
2023
entrez:
12
6
2023
Statut:
ppublish
Résumé
In the review, current status of sulfoxides on the pharmaceutical market is discussed. In the first part of the article, natural sulfoxides will be described with a special focus on sulforaphane and amanitin, a mushroom toxin which has been developed as payload in antibody drug conjugates in the possible cancer treatment. Controversies associated with the medical use of dimethylsulfoxide are briefly described in the next section. In the part devoted to PPIs, the benefits of using pure enantiomers (chiral switch) are discussed. An interesting approach, repositioning of drugs is exemplified by new possible applications of modafinil and sulindac. The review is concluded by presentation of cenicriviroc and adezmapimod, both with the status of promising drug candidates.
Identifiants
pubmed: 37307682
pii: S1367-5931(23)00078-9
doi: 10.1016/j.cbpa.2023.102340
pii:
doi:
Substances chimiques
Sulfoxides
0
Dimethyl Sulfoxide
YOW8V9698H
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102340Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.